(Q79385062)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17129076%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

title

Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17129076%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference

James R Spalding

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17129076%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Joel Hay

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17129076%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

publication date

1 January 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17129076%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17129076%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17129076%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17129076%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

page(s)

1221-1232

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17129076%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00019053-200624120-00006

22 December 2019

exact match

0 references

cites work

Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials

1 reference

12 December 2020

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

12 December 2020

Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

1 reference

12 December 2020

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

12 December 2020

New antibody approved for treatment of rheumatoid arthritis

1 reference

12 December 2020

Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis.

1 reference

12 December 2020

Guidelines for the management of rheumatoid arthritis: 2002 Update

1 reference

12 December 2020

Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis

1 reference

12 December 2020

Association between etanercept use and employment outcomes among patients with rheumatoid arthritis

1 reference

12 December 2020

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

12 December 2020

Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins

1 reference

12 December 2020

Evaluation and review of pharmacoeconomic models

1 reference

12 December 2020

Modeling the lifetime costs of rheumatoid arthritis.

1 reference

12 December 2020

Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.

1 reference

12 December 2020

The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial.

1 reference

12 December 2020

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

1 reference

12 December 2020

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis

1 reference

12 December 2020

An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists

1 reference

12 December 2020

An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline

1 reference

12 December 2020

Economic burden of rheumatoid arthritis: a systematic review

1 reference

12 December 2020

Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study

1 reference

12 December 2020

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

12 December 2020

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

12 December 2020

The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis

1 reference

12 December 2020

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

12 December 2020

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

12 December 2020

Switching between biological agents.

1 reference

12 December 2020

Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians

1 reference

12 December 2020

Adult and juvenile rheumatoid arthritis: current epidemiologic concepts

1 reference

12 December 2020

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes

1 reference

12 December 2020

Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis

1 reference

12 December 2020

The mortality of rheumatoid arthritis

1 reference

12 December 2020

Economic consequences of the progression of rheumatoid arthritis in Sweden

1 reference

12 December 2020

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients

1 reference

12 December 2020

The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study

1 reference

12 December 2020

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.

1 reference

12 December 2020

Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS).

1 reference

12 December 2020

Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.

1 reference

12 December 2020